Silo Pharma, Inc. SILO
1.75
0.00
0.00%
as of 25 Sep
- Market cap
- $2.8M
- P/E
- 0.0×
Follow SILO
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (91.23%) | (99.94%) | (74.56%) | (86.11%) |
+8 more TTM periods Free account |
|
| (70.96%) | (74.98%) | (56.30%) | (67.91%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(96.21%) | (79.41%) | (62.75%) | (93.05%) | |
Average Days of Receivables |
— | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(3.57) | (4.15) | (8.34) | (7.71) | |
Free Cash Flow |
(3.92) | (3.80) | (4.66) | (4.80) | |
Capital Expenditures |
(0.58) | 0.05 | — | — | |
Piotroski F-Score |
— | 2.00 | 3.00 | 3.00 | |
| Other line items | |||||
Cash ROIC |
(33.03%) | (32.81%) | (35.41%) | (44.12%) | |
Accounts Receivable Turnover |
— | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.07 | 0.04 | 0.03 | |
Inventory Turnover |
— | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 3,631.06 | 4,752.40 | 9,214.80 | |
Days of Inventory on Hand |
— | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 3,583.47% | 3,001.11% | 4,158.75% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 3,069.03% | 2,982.92% | 3,278.06% | |
Share Based Compensation of Revenue |
0.00% | 1,952.50% | 884.17% | 817.36% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.75 | 0.79 | 1.10 | 0.95 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
(5.75) | 1.19 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.08 | 0.13 | 0.12 | |
Operating CF per Share |
(3.04) | (4.20) | (8.34) | (7.71) | |
Capex per Share |
(0.53) | 0.05 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | (0.63) | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | (6,726.81%) | (5,871.67%) | (7,050.97%) |
Columns are period end dates